Nurix Therapeutics, Inc. Common stock (NRIX)
Nurix Therapeutics, Inc. is a biotechnology company focused on developing innovative small molecule therapies that modulate the ubiquitin-proteasome system to treat cancer, autoimmune, and inflammatory diseases. The company's approach involves targeting protein degradation pathways to selectively manipulate cellular processes and restore healthy function. Founded to advance precision medicine, Nurix leverages its expertise in drug discovery to develop targeted therapeutics with potential for broad clinical applications.
Company News
Nurix Therapeutics launched a pivotal Phase 2 clinical trial (DAYBreak) for bexobrutideg, a potential BTK degrader treatment for relapsed or refractory chronic lymphocytic leukemia, with plans for a Phase 3 confirmatory study in 2026.
Sanofi agreed to acquire Blueprint Medicines for $9.5 billion, including the rare immunology disease medicine Ayvakit and a promising pipeline. The deal will expand Sanofi's rare and immunology portfolios.
Beyond Air (XAIR) delivered earnings and revenue surprises of 23.40% and 33.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
NYCB stock benefits from news it is snapping up some assets of failed Signature Bank.
The clinical-stage biopharmaceutical company posted positive news regarding its lead therapy -- a BTK inhibitor that could fight certain blood-based cancers.